Merck & Co., Inc. (NYSE:MRK) Given New $100.00 Price Target at Mizuho

Share on StockTwits

Merck & Co., Inc. (NYSE:MRK) had its price objective raised by Mizuho from $97.00 to $100.00 in a report released on Wednesday, October 30th, The Fly reports. Mizuho currently has a buy rating on the stock.

MRK has been the topic of several other research reports. Societe Generale set a $105.00 target price on shares of Merck & Co., Inc. and gave the company a buy rating in a report on Tuesday, September 3rd. Svb Leerink initiated coverage on shares of Merck & Co., Inc. in a report on Friday, August 16th. They issued an outperform rating and a $103.00 target price on the stock. Leerink Swann initiated coverage on shares of Merck & Co., Inc. in a report on Thursday, August 15th. They issued an outperform rating and a $103.00 target price on the stock. ValuEngine downgraded shares of Merck & Co., Inc. from a hold rating to a sell rating in a report on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. set a $96.00 target price on shares of Merck & Co., Inc. and gave the company a buy rating in a report on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating to the company’s stock. Merck & Co., Inc. currently has an average rating of Buy and a consensus price target of $95.13.

Shares of MRK traded up $0.71 during midday trading on Wednesday, reaching $83.59. The stock had a trading volume of 6,053,527 shares, compared to its average volume of 10,105,755. Merck & Co., Inc. has a 1-year low of $70.89 and a 1-year high of $87.35. The company’s fifty day simple moving average is $84.01 and its two-hundred day simple moving average is $82.77. The company has a market cap of $212.31 billion, a price-to-earnings ratio of 19.26, a PEG ratio of 1.80 and a beta of 0.54. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a net margin of 20.26% and a return on equity of 47.94%. The firm had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. During the same period last year, the business earned $1.19 EPS. Merck & Co., Inc.’s revenue for the quarter was up 14.9% compared to the same quarter last year. On average, sell-side analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Bath Savings Trust Co grew its stake in Merck & Co., Inc. by 67.8% during the second quarter. Bath Savings Trust Co now owns 6,799 shares of the company’s stock worth $570,000 after buying an additional 2,746 shares during the period. Pensionfund DSM Netherlands purchased a new stake in Merck & Co., Inc. during the second quarter worth approximately $5,953,000. Pensionfund Sabic purchased a new stake in Merck & Co., Inc. during the second quarter worth approximately $3,941,000. South Texas Money Management Ltd. grew its stake in Merck & Co., Inc. by 0.5% during the second quarter. South Texas Money Management Ltd. now owns 645,800 shares of the company’s stock worth $54,150,000 after buying an additional 2,952 shares during the period. Finally, Stillwater Investment Management LLC grew its stake in Merck & Co., Inc. by 2.6% during the second quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock worth $402,000 after buying an additional 120 shares during the period. 74.95% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: What Does a Sell-Side Analyst Rating Mean?

The Fly

Analyst Recommendations for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.